Wei Zheng

RA Capital Management LP (RA Capital) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in Boston, Massachusetts. The firm was founded by Peter Kolchinsky in 2004. RA Capital provides discretionary investment advisory services to Healthcare Funds and the Nexus Funds which are open only to certain financially sophisticated and high net-worth individuals and entities.

Crown Bioscience, Inc. provides biomedical outsourcing solutions. It provides syngeneic and xenograft tumor models and custom model development and drug testing. The firm produces antibodies for therapeutic, diagnostic and theranostic applications. It also offers preclinical and drug development for anti-cancers therapeutics. The company was founded by Dr. Yiyou Chen, Dr. Yue Alexander Wu, Dr. William Pan and Dr. Faming Zhang in 2006 and is headquartered in Santa Clara, CA.

University of Washington functions as a College/University. The company is headquartered in Seattle, WA.

Part of Cubist Pharmaceuticals LLC, Terragen Discovery, Inc. is a developer of antibiotics and patent drugs. The company is based in Vancouver, Canada. Terragen Discovery was acquired by Cubist Pharmaceuticals LLC on October 26, 2000 for $25.61 million.

Case Western Reserve University provides educational services. It offers a variety of undergraduate degree courses and graduate and professional options such as arts and sciences, dentistry, engineering, law, management, medicine, nursing, social work, and more. The firm also offers dual-degree programs. The company was founded in 1826 and is headquartered in Cleveland, OH.

Delphon Industries LLC engages in the provision of polymer and adhesive solutions. It offers specialty elastomer films, adhesive materials, and proprietary products. The company was founded in 1982 and is headquartered in Hayward, CA.

Qiming Venture Partners Ltd (Qiming Venture Partners) is a venture capital subsidiary of Qiming Caymen Ltd founded in 2006 by Gary Rieschel, Zi Ping Kuang and Ignition Partners LLC. The firm is headquartered in Shanghai, China.

Moody's Analytics, Inc. provides financial intelligence and analytical tools. It offers asset and liability management, credit origination, and regulatory and accounting solutions. The company was founded in January 2008 and is headquartered in New York, NY.

Tsinghua Yuanxing Biotechnology, Inc. is engaged in the development of biological and pharmaceutical products. It is involved in the research and development, commercialization of adenoviral vector vaccine. The company was founded on December 4, 2000 and is headquartered in Shenzhen, China.

Solta Medical, Inc. designs, develops, manufactures and markets energy-based medical device systems for aesthetic applications. Its brands include Clear + Brilliant pélo, Thermage, Liposonix, VASER, Fraxel, Clear + Brilliant, and Isolaz systems which are used to address various aesthetic issues. The company was founded by Edward W. Knowlton on January 11, 1996 and is headquartered in Pleasanton, CA.

CANbridge Life Sciences Ltd. produces biopharmaceutical products. It engages in the research and development of therapeutic drug treatment for critical medical condition. The company was founded by James Xue on June 12, 2012 and is headquartered in Chaoyang, China.

Part of Banque Pictet & Cie SA, Pictet & Cie Group SCA is a Swiss company specialized in wealth management, asset management, and asset servicing. The company is based in Carouge, Switzerland. With over 200 years of investment leadership, Pictet & Cie Group can help clients with their financial needs.

Columbia Threadneedle Investments (Missouri) provides investment services. Its products include mutual fund, managed accounts, exchange traded funds, 529 plan, variable products, and close-end funds. The company is headquartered in Hazelwood, MO.

Abbisko Therapeutics Co., Ltd. engages in the research and development of biomedicine and biotechnology. Its business includes technology transfer, technical advisory, and technical services. The company was founded on April 12, 2016 and is headquartered in Shanghai, China.

InSilico Medicine Hong Kong Ltd. operates as bioinformatics company, which utilizes advances in genomics, big data analysis and deep learning for silico drug discovery and drug repurposing for aging and age-related diseases. The company was founded by Alex Zhavoronkov and is headquartered in Hong Kong.

Antengene Corporation Co., Ltd. operates as a holding company. It engages in clinical development of drug candidates. The company was founded on June 15, 2016 and is headquartered in Shanghai, China.

Part of 89bio, Inc., 89Bio Ltd. is an Israeli company that develops therapies and drugs for the treatment of patients living with nonalcoholic steatohepatitis. The company is based in Herzliya, Israel.

Part of InSilico Medicine Hong Kong Ltd., InSilico Medicine, Inc. is a clinical stage biotechnology company based in New York, NY. InSilico Medicine is focused on generative models, reinforcement learning, and other modern machine learning techniques for the generation of new molecular structures with specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. InSilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. The company was founded in 2014 by Aleksandr Aliper and Aleksandrs Zhavoronkov. Aleksandrs Zhavoronkov has been the CEO since 2014.

InSilico Medicine Cayman TopCo is a holding company, which engages in the research and development of generative artificial intelligence (AI) driven therapeutic pipeline and software licensing. Its pipeline targets areas include high unmet needs, with a footprint in fibrosis, oncology, immunology, and other therapeutic areas. The company was founded by Alex Zhavoronkov on November 19, 2018 and is headquartered in Hong Kong.

Zion Pharma Ltd. is a private, Chinese clinical stage biotech company founded in 2018. The company's research operations are located in mainland China and they have additional research operations elsewhere. The company is based in China and has subsidiaries in the country. The company is focused on developing novel, small molecule, anti-tumoral agents using an innovative drug discovery approach. Zion Pharma is capitalizing on its dmpk expertise to develop a pipeline of proprietary first-in-class/best-in-class compounds focused on therapeutic targets which drive tumor inhibition, including ataxia telangiectasia mutated (atm), kirsten rat sarcoma (kras g12d) and smarca2 (brm).